Details for Patent: 9,914,738

Which drugs does patent 9,914,738 protect, and when does it expire?

Patent 9,914,738 protects BYFAVO and is included in one NDA.

This patent has thirty-two patent family members in nineteen countries.

Summary for Patent: 9,914,738

Title:	Short-acting benzodiazepine salts and their polymorphic forms
Abstract:	The invention relates to besylate salts of the compound of formula (I): Methods of preparing the salts, and their use as medicaments, in particular for sedative or hypnotic, anxiolytic, muscle relaxant, or anticonvulsant purposes is also described.
Inventor(s):	Gary Stuart Tilbrook, Louisa Jane Quegan
Assignee:	Paion UK Ltd
Application Number:	US15/703,945
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Device; Dosage form;

error: insufficient information

Drugs Protected by US Patent 9,914,738

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Acacia	BYFAVO	remimazolam besylate	POWDER;INTRAVENOUS	212295-001	Oct 6, 2020		RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 9,914,738

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0613692.3	Jul 10, 2006
United Kingdom	0613694.9	Jul 10, 2006

International Family Members for US Patent 9,914,738

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E480532
Australia	2007274054
Brazil	PI0714886
Canada	2657347